A. Pie graph of the percentage of actionable aberrations in
the indicated targets or target pathways for the 73 patients who received at
least one matched drug. Since some patients had alterations targeted in multiple
genes or pathways, the percentages do not add up to 100%. “Immune
checkpoints” refers to amplification of the CD274
(PD-L1) and/or PDCD1LG2
(PD-L2) genes, positive PD-L1 expression
(immunohistochemistry), high/intermediate tumor mutational burden, or high
microsatellite instability; “MAPK pathway” refers to alterations
in the KRAS, BRAF, GNAS, MEK1, NF2 or
JAK2 genes; “ERBB pathway” refers to
alterations in the ERBB2 or ERBB3 genes;
“PI3K pathway” refers to alterations in the AKT1, AKT2,
PIK3CA, PIK3R1 or PTEN genes;
“FGF/FGFR” pathway refers to alterations/amplifications in the
FGFR1/2/3, FGF3, FGF4, FGF6, FGF19, FGF23 or
FRS2 genes; “Beta-catenin pathway” refers to
alterations in the APC, CTNNB1 or FAT1 genes;
“Cell cycle regulation” refers to alterations in the
CDKN2A/B, CCND1/2 or CDK4/6 genes;
“HGF/MET pathway” refers to alterations in the
HGF or MET genes; “BRCA
complex” refers to alterations in the BRCA1, BRCA2, ATM,
BRIP or PALB2 genes; Estrogen receptor”
refers to alterations in the ESR1 gene or estrogen receptor
(ER) positivity as assessed by immunohistochemistry; “Other”
refers to alterations in the MYC or EWSR1
genes. TP53, EGFR, PTCH1, and
RET refer to alterations in the genes encoding these
proteins.
B. Pie graph of the percentage of actionable aberrations in
the indicated targets or target pathways for the 28 patients who had a Matching
Score >50%. In these 28 patients, a total of 67 molecular alterations
were matched to treatments.
C. Bar graph analyzing the percentage of patients with SD
≥6 months, partial response (PR), and complete response (CR) for patients
with a Matching Score of ≤50% (N=49) versus >50% (N=20). P-values
were computed using a binary logistic regression test.
D. Bar graph analyzing the percentage of patients with a
PFS ratio ≥1.3 versus PFS<1.3 for patients with a Matching Score
of ≤50% (N=49) versus >50% (N=20). P-values were computed using a
binary logistic regression test.
E. Kaplan-Meier curves display progression-free survival
(PFS) for patients with a Matching Score ≤50% (N=55) versus >50%
(N=28). P-values are from the log-rank test (two-sided)
F. Kaplan-Meier curves display overall survival (OS) for
patients with a Matching Score ≤50% (N=55) versus >50% (N=28).
P-values are from the log-rank test (two-sided). *Median OS not reached after a
median follow up of 8.5 months.